Nuclear Medicine Dosimetry in Imaging and Therapy
W Bolch1*, C Lawhn Heath2*, W Erwin3*, S St. James4*, (1) University of Florida, Gainesville, Florida, (2) University Of California San Francisco, San Francisco, CA, (3) UT MD Anderson Cancer Center, Houston, TX, (4) UCSF, San Francisco, CA
Presentations
1:27 PM Clinical Perspective on Therapeutic Nuclear Medicine - C Lawhn Heath, Presenting Author
1:54 PM Practical Dosimetry for Therapeutic Nuclear Medicine, MIBG - W Erwin, Presenting Author
2:21 PM Practical Dosimetry for Therapeutic Nuclear Medicine, 177Lu Based Therapies - S St. James, Presenting Author
2:48 PM Audience Q & A - S St. James, Presenting Author
TU-CD-TRACK 2-0 (Tuesday, 7/27/2021) 1:00 PM - 3:00 PM [Eastern Time (GMT-4)]
In Nuclear Medicine imaging and therapy applications, molecularly targeted radionuclides may be used to either provide medical images or to deliver a therapeutic dose of radiation. Across this wide range of applications, there are different methods of estimating the organ and tumor doses received by the patient. In this session, dose calculations for nuclear medicine imaging applications will be discussed along with the need for accurate dose calculations in the therapeutic setting. The session will conclude with a discussion of the current methodologies for dose calculations for therapeutic applications including 131I-MIBG, 177Lu-DOTATATE and 177Lu-PSMA.
Learning Objectives:
1. Understanding the MIRD schema for assessment of radiation dose at multiple anatomic levels.
2. Understanding fixed activity versus dosimetry driven treatment planning
3. To become familiar with the current methodology for I131-MIBG dosimetry based treatment planning.
4.To become familiar with the requirements for patient specific dosimetry for 177-Lu based therapies.
Handouts
- 166-57987-15651646-170948-326611318.pdf (Wesley Bolch)
- 166-57989-15651646-171097-1715366795.pdf (William Erwin)
Keywords
Not Applicable / None Entered.
Taxonomy
Not Applicable / None Entered.
Contact Email